Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

High levels of lipoprotein (a)[Lp (a)], an apoB100-containing lipoprotein, are an independent
and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms …

Large-scale genome-wide association studies conducted over the last decade have
uncovered numerous genetic variants associated with cardiometabolic traits and risk factors …

Objective: Lp (a)(lipoprotein [a]) concentrations are associated with atherosclerotic
cardiovascular disease (ASCVD), and new therapies that enable potent and specific …

Background Lipoprotein (a) levels are genetically determined and, when elevated, are a risk
factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic …

Background High lipoprotein (a) concentrations present in 10%–20% of the population have
long been linked to increased risk of ischemic cardiovascular disease. It is unclear whether …

Abstract High lipoprotein (a)[Lp (a)] concentrations are one of the most important genetically
determined risk factors for cardiovascular disease. Lp (a) concentrations are an enigmatic …

Importance Human genetic studies have indicated that plasma lipoprotein (a)(Lp [a]) is
causally associated with the risk of coronary heart disease (CHD), but randomized trials of …

Coronary artery disease is the leading global cause of mortality. Long recognized to be
heritable, recent advances have started to unravel the genetic architecture of the disease …

Pathophysiological, epidemiological, and genetic studies provide strong evidence that
lipoprotein (a)[Lp (a)] is a causal mediator of cardiovascular disease (CVD) and calcific …